{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T04:57:19Z","timestamp":1789102639923,"version":"build-2803163510"},"reference-count":80,"publisher":"Elsevier","isbn-type":[{"value":"9780128122266","type":"print"}],"license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017]]},"DOI":"10.1016\/bs.podrm.2017.02.005","type":"book-chapter","created":{"date-parts":[[2017,3,31]],"date-time":"2017-03-31T22:00:56Z","timestamp":1490997656000},"page":"241-286","source":"Crossref","is-referenced-by-count":11,"title":["Olmesartan"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.podrm.2017.02.005_bb0005","series-title":"Pharmaceuticals, Body Fluids and Postmortem Material","first-page":"1819","article-title":"Clarke's analysis of drugs and poisons","author":"Moffat","year":"2011"},{"key":"10.1016\/bs.podrm.2017.02.005_bb0010","series-title":"Martindale: The Complete Drug Reference","author":"Sweetman","year":"2009"},{"key":"10.1016\/bs.podrm.2017.02.005_bb0015","unstructured":"https:\/\/www.tocris.com\/dispprod.php?ItemId=354439#.VtUfhdJEkdU."},{"key":"10.1016\/bs.podrm.2017.02.005_bb0020","series-title":"The Merck Index: An Encyclopedia of Chemicals, Drugs and Biologicals","author":"O'Neil","year":"2006"},{"key":"10.1016\/bs.podrm.2017.02.005_bb0025","unstructured":"British Pharmacopoeia, 2015, Stationery Office, first ed."},{"key":"10.1016\/bs.podrm.2017.02.005_bb0030","first-page":"26","article-title":"An efficient and large scale synthesis of olmesartan medoxomil: anti hypertensive drug","volume":"3","author":"Rajua","year":"2013","journal-title":"Chem. Biol. Interface"},{"issue":"2","key":"10.1016\/bs.podrm.2017.02.005_bb0035","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1080\/00397910802372558","article-title":"Efficient synthesis of olmesartan medoxomil, an antihypertensive drug","volume":"39","author":"Babu","year":"2008","journal-title":"Synth. Commun."},{"issue":"12","key":"10.1016\/bs.podrm.2017.02.005_bb0040","doi-asserted-by":"crossref","first-page":"21346","DOI":"10.3390\/molecules201219762","article-title":"Synthesis and physicochemical characterization of the process-related impurities of olmesartan medoxomil. Do 5-(biphenyl-2-yl)-1-triphenylmethyltetrazole intermediates in sartan syntheses exist?","volume":"20","author":"Dams","year":"2015","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/bs.podrm.2017.02.005_bb0045","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1021\/jm950450f","article-title":"Nonpeptide angiotensin II receptor antagonists: synthesis, biological activities, and structure-activity relationships of imidazole-5-carboxylic acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position and their related compounds","volume":"39","author":"Yanagisawa","year":"1996","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.podrm.2017.02.005_bb0050","unstructured":"H. Yanagisawa, Y. Shimoji, K. Fujimoto, T. Kanazaki, Y. Anemiya, H. Koike, T. Sada, 1-Biphenylimidazole derivatives, their preparation and their therapeutic use, Patent EP 503785, 1992, p. A1."},{"key":"10.1016\/bs.podrm.2017.02.005_bb0055","unstructured":"https:\/\/www.tga.gov.au\/auspar\/auspar-hydrochlorothiazide-olmesartan-medoxomil-amlodipine-besilate."},{"key":"10.1016\/bs.podrm.2017.02.005_bb0060","unstructured":"http:\/\/www.drugbank.ca\/drugs\/DB00275#properties."},{"key":"10.1016\/bs.podrm.2017.02.005_bb0065","unstructured":"A. Becker, Crystalline form b of olmesartan medoxomil, Patent application US 12\/602,948, 2008."},{"key":"10.1016\/bs.podrm.2017.02.005_bb0070","unstructured":"http:\/\/www.chemicalland21.com\/specialtychem\/nd\/OLMESARTAN%20MEDOXOMIL.pdf."},{"key":"10.1016\/bs.podrm.2017.02.005_bb0075","unstructured":"http:\/\/www.chemnet.com\/cas\/en\/144689-63-4\/Olmesartan-Medoxomil.html."},{"key":"10.1016\/bs.podrm.2017.02.005_bb0080","unstructured":"http:\/\/toxnet.nlm.nih.gov\/cgi-bin\/sis\/search\/a?dbs+hsdb:@term+@DOCNO+8214."},{"key":"10.1016\/bs.podrm.2017.02.005_bb0085","unstructured":"USP Monograph, Olmesartan USP 37\u2013NF 32, O.M., 2014."},{"issue":"5","key":"10.1016\/bs.podrm.2017.02.005_bb0090","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1039\/c2ay26138c","article-title":"Validated voltammetric determination of olmesartan medoxomil: method development and electrochemical behaviors investigation","volume":"5","author":"Celebier","year":"2013","journal-title":"Anal. Methods"},{"key":"10.1016\/bs.podrm.2017.02.005_bb0095","first-page":"920","article-title":"Electrochemical studies of olmesartan medoxomil and its detection in pharmaceutical dosage forms and biological fluids by cathodic adsorptive stripping voltammetric method","volume":"25","author":"\u00d6zt\u00fcrk","year":"2014","journal-title":"J. Braz. Chem. Soc."},{"key":"10.1016\/bs.podrm.2017.02.005_bb0100","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.saa.2014.01.095","article-title":"Spectrophotometric methods for simultaneous determination of ternary mixture of amlodipine besylate, olmesartan medoxomil and hydrochlorothiazide","volume":"125","author":"Merey","year":"2014","journal-title":"Spectrochim. Acta A Mol. Biomol. Spectrosc."},{"issue":"1","key":"10.1016\/bs.podrm.2017.02.005_bb0105","doi-asserted-by":"crossref","first-page":"111","DOI":"10.4103\/0250-474X.62245","article-title":"Spectrophotometric estimation of olmesartan medoxomil and hydrochlorothiazide in tablet","volume":"72","author":"Rote","year":"2010","journal-title":"Indian J. Pharm. Sci."},{"issue":"1","key":"10.1016\/bs.podrm.2017.02.005_bb0110","doi-asserted-by":"crossref","first-page":"36","DOI":"10.4103\/2229-4708.81092","article-title":"Development of the UV spectrophotometric method of olmesartan medoxomil in bulk drug and pharmaceutical formulation and stress degradation studies","volume":"2","author":"Patel","year":"2011","journal-title":"Pharm. Methods"},{"issue":"5","key":"10.1016\/bs.podrm.2017.02.005_bb0115","doi-asserted-by":"crossref","first-page":"505","DOI":"10.4103\/0250-474X.58176","article-title":"Derivative and Q-analysis spectrophotometric methods for estimation of hydrochlorothiazide and olmesartan medoxomil in tablets","volume":"71","author":"Bhusari","year":"2009","journal-title":"Indian J. Pharm. Sci."},{"issue":"6","key":"10.1016\/bs.podrm.2017.02.005_bb0120","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1134\/S1061934813060087","article-title":"New spectrophotometric and spectrofluorimetric methods for the determination of angiotensin II receptor antagonists in tablets and plasma","volume":"68","author":"Tekkeli","year":"2013","journal-title":"J. Anal. Chem."},{"issue":"3","key":"10.1016\/bs.podrm.2017.02.005_bb0125","first-page":"1","article-title":"Absorbance correction method for simultaneous determination of olmesartan medoxomil and hydrochlorothiazide in combined tablet dosage form","volume":"6","author":"Patel","year":"2015","journal-title":"Pharm. Sin."},{"issue":"2","key":"10.1016\/bs.podrm.2017.02.005_bb0130","first-page":"97","article-title":"Development and validation of spectrophotometric method for simultaneous determination of cilnidipine and olmesartan medoxomil in tablet dosage form","volume":"4","author":"Sidhdhapara","year":"2014","journal-title":"Int. J. Pharm. Biol. Sci."},{"issue":"6","key":"10.1016\/bs.podrm.2017.02.005_bb0135","first-page":"160","article-title":"Development and validation of spectrophotometric method for simultaneous estimation of olmesartan medoxomil and cilnidipine by simultaneous equation method","volume":"2","author":"Ghelani","year":"2014","journal-title":"PharmaTutor"},{"issue":"1","key":"10.1016\/bs.podrm.2017.02.005_bb0140","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2478\/acph-2014-0008","article-title":"High throughput microwell spectrophotometric assay for olmesartan medoxomil in tablets based on its charge-transfer reaction with DDQ","volume":"64","author":"Darwish","year":"2014","journal-title":"Acta Pharm."},{"issue":"10","key":"10.1016\/bs.podrm.2017.02.005_bb0145","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1134\/S1061934814100116","article-title":"Simultaneous determination and validation of some binary mixtures of antihypertensive drugs using ratio derivative spectrophotometric method","volume":"69","author":"Kurbanoglu","year":"2014","journal-title":"J. Anal. Chem."},{"issue":"1","key":"10.1016\/bs.podrm.2017.02.005_bb0150","first-page":"1","article-title":"Simultaneous estimation of metaprolol succinate and olmesartan medoxomil from capsule dosage form by first order derivative spectroscopic method","volume":"40","author":"Jadhav","year":"2013","journal-title":"Mahidol Univ. J. Pharm. Sci."},{"key":"10.1016\/bs.podrm.2017.02.005_bb0155","first-page":"78","article-title":"Simultaneous first derivative UV spectrophotometric estimation of ramipril and olmesartan","volume":"2","author":"Karajgi","year":"2012","journal-title":"J. Pharm. Sci."},{"issue":"4","key":"10.1016\/bs.podrm.2017.02.005_bb0160","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1155\/2010\/826585","article-title":"UV Spectrophotometric determination of hydrochlorothiazide and olmesartan medoxomil in pharmaceutical formulation","volume":"7","author":"Hemke","year":"2010","journal-title":"J. Chem."},{"issue":"2","key":"10.1016\/bs.podrm.2017.02.005_bb0165","first-page":"122","article-title":"Validated kinetic spectrophotometric determination of candesartan cilexetil and olmesartan medoxomil using alkaline permanganate oxidation","volume":"6","author":"Hassan","year":"2014","journal-title":"Der Pharma Chem."},{"key":"10.1016\/bs.podrm.2017.02.005_bb0170","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1155\/2013\/870579","article-title":"Formulation and evaluation of liquisolid compacts for olmesartan medoxomil","volume":"2013","author":"Prajapati","year":"2013","journal-title":"J. Drug Deliv."},{"issue":"4","key":"10.1016\/bs.podrm.2017.02.005_bb0175","first-page":"1599","article-title":"New spectrofluorimetric methods for the simultaneous determination of olmesartan medoxomil and amlodipine besylate in their combined tablets","volume":"7","author":"Darwish","year":"2012","journal-title":"Dig. J. Nanomater. Biostruct."},{"issue":"1","key":"10.1016\/bs.podrm.2017.02.005_bb0180","first-page":"300","article-title":"Simple novel spectrophotometric and spectrofluorimetric methods for determination of some anti-hypertensive drugs","volume":"7","author":"Farouk","year":"2011","journal-title":"J. Am. Sci."},{"issue":"1","key":"10.1016\/bs.podrm.2017.02.005_bb0185","first-page":"108","article-title":"Application of capillary electrophoresis to investigate the degradation kinetic of olmesartan medoxomil","volume":"28","author":"Celebier","year":"2009","journal-title":"Lat. Am. J. Pharm."},{"issue":"2","key":"10.1016\/bs.podrm.2017.02.005_bb0190","first-page":"119","article-title":"Development of a capillary zone electrophoresis method for the indirect determination of olmesartan medoxomil and determination of hydrochlorothiazide in synthetic tablets","volume":"27","author":"\u00c7elebier","year":"2007","journal-title":"Hacettepe Univ. J. Faculty Pharm."},{"issue":"11\u201312","key":"10.1016\/bs.podrm.2017.02.005_bb0195","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1365\/s10337-009-1094-z","article-title":"RP-LC and HPTLC methods for the determination of olmesartan medoxomil and hydrochlorothiazide in combined tablet dosage forms","volume":"69","author":"Bari","year":"2009","journal-title":"Chromatographia"},{"issue":"1","key":"10.1016\/bs.podrm.2017.02.005_bb0200","first-page":"209","article-title":"HPTLC method for estimation of olmesartan medoxomil in tablet formulation with stability studies","volume":"26","author":"Verma","year":"2013","journal-title":"Pak. J. Pharm. Sci."},{"issue":"2","key":"10.1016\/bs.podrm.2017.02.005_bb0205","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1080\/00032710903325906","article-title":"Validated HPLC and HPTLC method for simultaneous quantitation of amlodipine besylate and olmesartan medoxomil in bulk drug and formulation","volume":"43","author":"Kamble","year":"2010","journal-title":"Anal. Lett."},{"issue":"3","key":"10.1016\/bs.podrm.2017.02.005_bb0210","doi-asserted-by":"crossref","first-page":"791","DOI":"10.5740\/jaoacint.11-204","article-title":"Simultaneous determination of atorvastatin calcium and olmesartan medoxomil in a pharmaceutical formulation by reversed phase high-performance liquid chromatography, high-performance thin-layer chromatography, and UV spectrophotometric methods","volume":"97","author":"Soni","year":"2014","journal-title":"J. AOAC Int."},{"issue":"2","key":"10.1016\/bs.podrm.2017.02.005_bb0215","doi-asserted-by":"crossref","first-page":"354","DOI":"10.5740\/jaoacint.14-179","article-title":"HPTLC with fluorescence densitometry for simultaneous determination of some angiotensin II receptor blockers in tablets and plasma","volume":"98","author":"Hussein","year":"2015","journal-title":"J. AOAC Int."},{"issue":"2","key":"10.1016\/bs.podrm.2017.02.005_bb0220","doi-asserted-by":"crossref","first-page":"88","DOI":"10.4103\/0975-1483.96622","article-title":"Simultaneous quantitative analysis of olmesartan medoxomil and amlodipine besylate in plasma by high-performance liquid chromatography technique","volume":"4","author":"Shah","year":"2012","journal-title":"J. Young Pharm."},{"issue":"6","key":"10.1016\/bs.podrm.2017.02.005_bb0225","first-page":"208","article-title":"Development of RP-HPLC method for estimation of olmesartan medoxomil in tablet dosage forms","volume":"3","author":"Prasad","year":"2011","journal-title":"Der Pharma Chem."},{"issue":"3\u20134","key":"10.1016\/bs.podrm.2017.02.005_bb0230","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1365\/s10337-007-0304-9","article-title":"Simultaneous HPLC analysis of olmesartan and hydrochlorothiazide in combined tablets and in vitro dissolution studies","volume":"66","author":"Sagirli","year":"2007","journal-title":"Chromatographia"},{"issue":"2","key":"10.1016\/bs.podrm.2017.02.005_bb0235","first-page":"145","article-title":"New RP-HPLC method for the determination of olmesartan medoxomil in tablet dosage form","volume":"5","author":"Ganduri","year":"2010","journal-title":"Eurasian J. Anal. Chem."},{"issue":"1","key":"10.1016\/bs.podrm.2017.02.005_bb0240","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jchromb.2007.05.049","article-title":"Quantitative determination of olmesartan in human plasma and urine by liquid chromatography coupled to tandem mass spectrometry","volume":"856","author":"Liu","year":"2007","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/bs.podrm.2017.02.005_bb0245","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jchromb.2013.08.026","article-title":"Simultaneous determination of olmesartan and amlodipine in human plasma and urine by ultra performance liquid chromatography tandem mass spectrometry","volume":"938","author":"Qi","year":"2013","journal-title":"J. Chromatogr. B"},{"issue":"1","key":"10.1016\/bs.podrm.2017.02.005_bb0250","doi-asserted-by":"crossref","first-page":"50","DOI":"10.4236\/ajac.2012.31008","article-title":"Rapid simultaneous determination of olmesartan, amlodipine and hydrochlorothiazide in combined pharmaceutical dosage form by stability-indicating ultra performance liquid chromatography","volume":"3","author":"Kumar","year":"2012","journal-title":"Am. J. Anal. Chem."},{"issue":"7","key":"10.1016\/bs.podrm.2017.02.005_bb0255","first-page":"905","article-title":"Method development and validation of simultaneous analysis of olmesartan medoxomil and hydrochlorothiazide by UV and HPLC, their cross validation","volume":"4","author":"Singh","year":"2015","journal-title":"World J. Pharm. Pharm. Sci."},{"issue":"7","key":"10.1016\/bs.podrm.2017.02.005_bb0260","first-page":"321","article-title":"Development and validation of chromatographic method for the simultaneous estimation of olmesartan medoxomil, amlodipine besylate, cilnidipine in combination tablet dosage form","volume":"7","author":"Ravichandran","year":"2015","journal-title":"Int. J. Pharm. Pharm. Sci."},{"issue":"7","key":"10.1016\/bs.podrm.2017.02.005_bb0265","first-page":"21","article-title":"A stability indicating assay method development and validation for simultaneous estimation of olmesartan medoxomil and metoprolol succinate in bulk and pharmaceutical dosage form by RP-HPLC method","volume":"6","author":"Yunoos","year":"2015","journal-title":"Pharm. Sin."},{"key":"10.1016\/bs.podrm.2017.02.005_bb0270","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.talanta.2015.10.074","article-title":"Three-way analysis of the UPLC\u2013PDA dataset for the multicomponent quantitation of hydrochlorothiazide and olmesartan medoxomil in tablets by parallel factor analysis and three-way partial least squares","volume":"148","author":"Din\u00e7","year":"2016","journal-title":"Talanta"},{"issue":"5","key":"10.1016\/bs.podrm.2017.02.005_bb0275","first-page":"266","article-title":"Development and validation of RP-HPLC method for the simultaneous estimation of olmesartan medoxomil and chlorthalidone in tablet dosage form","volume":"7","author":"Sawale","year":"2015","journal-title":"Int. J. Pharm. Pharm. Sci."},{"issue":"2","key":"10.1016\/bs.podrm.2017.02.005_bb0280","doi-asserted-by":"crossref","first-page":"921","DOI":"10.13005\/ojc\/310236","article-title":"Method development and validation of RP-HPLC method for simultaneous estimation of olmesartan medoxomil and hydrochlorothiazide in bulk and pharmaceutical dosage form","volume":"31","author":"Gayathri","year":"2015","journal-title":"Orient. J. Chem."},{"key":"10.1016\/bs.podrm.2017.02.005_bb0285","first-page":"005","article-title":"Determination of olmesartan concentration in human plasma by HPLC fluorescence method","volume":"11","author":"Yufei","year":"2013","journal-title":"China Pharm."},{"issue":"1","key":"10.1016\/bs.podrm.2017.02.005_bb0290","first-page":"785","article-title":"RP-HPLC method development and validation for simultaneous estimation of cilnidipine and olmesartan medoxomil in combined tablet dosage form","volume":"4","author":"Ahmed","year":"2014","journal-title":"World J. Pharm. Pharm. Sci."},{"issue":"3","key":"10.1016\/bs.podrm.2017.02.005_bb0295","first-page":"714","article-title":"Development and validation of a reversed phase HPLC method for simultaneous estimation of olmesartan and hydrochlorothiazide in combined tablet dosage form","volume":"1","author":"Raja","year":"2011","journal-title":"Int. J. Res. Pharm. Chem."},{"issue":"9","key":"10.1016\/bs.podrm.2017.02.005_bb0300","first-page":"318","article-title":"Development and validation of RP-HPLC method for determination of hydrochlorothiazide, olmesartan medoxomil and their related substances in combined tablet dosage form","volume":"6","author":"Patel","year":"2014","journal-title":"Int. J. Pharm. Pharm. Sci."},{"issue":"4","key":"10.1016\/bs.podrm.2017.02.005_bb0305","doi-asserted-by":"crossref","first-page":"523","DOI":"10.7897\/2277-4343.054106","article-title":"Development and validation of RP-HPLC method for estimation of amlodipine besylate, olmesartan medoxomil and hydrochlorothiazide in tablet dosage form","volume":"5","author":"Jain","year":"2014","journal-title":"Int. J. Res. Ayurveda Pharm."},{"issue":"6","key":"10.1016\/bs.podrm.2017.02.005_bb0310","first-page":"881","article-title":"Analytical method development and validation for the estimation of olmesartan medoxomil by RP-UPLC in bulk and pharmaceutical dosage forms","volume":"1","author":"Pattan","year":"2013","journal-title":"Indian J. Res. Pharm. Biotechnol."},{"issue":"7","key":"10.1016\/bs.podrm.2017.02.005_bb0315","first-page":"508","article-title":"Development and validation of analytical method for simultaneous estimation of cilnidipine and olmesartan medoxomil in bulk and tablet dosage form by RP-HPLC","volume":"6","author":"Minase","year":"2014","journal-title":"Int. J. Pharm. Pharm. Sci."},{"issue":"2","key":"10.1016\/bs.podrm.2017.02.005_bb0320","first-page":"457","article-title":"Development and validation of an RP-HPLC method for the determination of olmesartan in human plasma","volume":"4","author":"Jyothirmai","year":"2014","journal-title":"Int. J. Res. Pharm. Chem."},{"issue":"2","key":"10.1016\/bs.podrm.2017.02.005_bb0325","first-page":"1115","article-title":"Development and validation of LC method for the simultaneous estimation of rosuvastatin calcium and olmesartan medoxomil in pharmaceutical dosage form","volume":"6","author":"Sharma","year":"2014","journal-title":"Int. J. ChemTech Res."},{"issue":"12","key":"10.1016\/bs.podrm.2017.02.005_bb0330","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.14233\/ajchem.2014.16330","article-title":"Sensitive liquid chromatographic assay for simultaneous determination of olmesartan and its prodrug olmesartan medoxomil in rabbit plasma","volume":"26","author":"Sharma","year":"2014","journal-title":"Asian J. Chem."},{"issue":"1","key":"10.1016\/bs.podrm.2017.02.005_bb0335","doi-asserted-by":"crossref","first-page":"195","DOI":"10.13005\/ojc\/300123","article-title":"Method development and validation for simultaneous estimation of olmesartan medoxomil and hydrochlorothiazide by RP-HPLC","volume":"30","author":"Vidyadhara","year":"2014","journal-title":"Orient. J. Chem."},{"issue":"1","key":"10.1016\/bs.podrm.2017.02.005_bb0340","first-page":"82","article-title":"Identification of related substances in olmesartan medoxomil by LC-MS\/MS","volume":"32","author":"Mswang","year":"2012","journal-title":"Chin. J. Pharm. Anal."},{"issue":"9","key":"10.1016\/bs.podrm.2017.02.005_bb0345","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jchromb.2010.01.009","article-title":"Simultaneous quantitative determination of olmesartan and hydrochlorothiazide in human plasma and urine by liquid chromatography coupled to tandem mass spectrometry","volume":"878","author":"Liu","year":"2010","journal-title":"J. Chromatogr. B"},{"issue":"2","key":"10.1016\/bs.podrm.2017.02.005_bb0350","first-page":"168","article-title":"Determination of olmesartan concentration by LC-MS-MS assay in the human plasma","author":"Chen","year":"2008","journal-title":"Central South Pharm."},{"issue":"3","key":"10.1016\/bs.podrm.2017.02.005_bb0355","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.jpba.2008.02.021","article-title":"Identification of a degradation product in stressed tablets of olmesartan medoxomil by the complementary use of HPLC hyphenated techniques","volume":"47","author":"Murakami","year":"2008","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"1\u20132","key":"10.1016\/bs.podrm.2017.02.005_bb0360","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1365\/s10337-008-0849-2","article-title":"Stability-indicating LC method for the determination of olmesartan in bulk drug and in pharmaceutical dosage form","volume":"69","author":"Rane","year":"2009","journal-title":"Chromatographia"},{"issue":"11\u201312","key":"10.1016\/bs.podrm.2017.02.005_bb0365","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1365\/s10337-008-0811-3","article-title":"Stability-indicating LC determination of a new antihypertensive, olmesartan medoxomil in tablets","volume":"68","author":"Bajerski","year":"2008","journal-title":"Chromatographia"},{"issue":"2","key":"10.1016\/bs.podrm.2017.02.005_bb0370","doi-asserted-by":"crossref","first-page":"153","DOI":"10.4236\/ajac.2012.32022","article-title":"Development and validation of stability indicating LC method for olmesartan medoxomil","volume":"3","author":"Rao","year":"2012","journal-title":"Am. J. Anal. Chem."},{"issue":"1","key":"10.1016\/bs.podrm.2017.02.005_bb0375","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1097\/00004872-200106001-00004","article-title":"The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction","volume":"19","author":"Laeis","year":"2001","journal-title":"J. Hypertens. Suppl."},{"issue":"1","key":"10.1016\/bs.podrm.2017.02.005_bb0380","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1097\/00004872-200106001-00005","article-title":"Olmesartan medoxomil: influence of age, renal and hepatic function on the pharmacokinetics of olmesartan medoxomil","volume":"19","author":"Von Bergmann","year":"2001","journal-title":"J. Hypertens. Suppl."},{"key":"10.1016\/bs.podrm.2017.02.005_bb9000","unstructured":"L.L. Brunton, J.S. Lazo, K.L. Parker, Chapter 30: Renin and angiotensin\u2014Edwin K. Jackson, in: L.L. Brunton (Ed.), Goodman & Gilman\u2019s, The Pharmacological Basis of Therapeutics, McGraw-Hill Medical Publishing Division, New York, 812\u2013814."},{"issue":"5","key":"10.1016\/bs.podrm.2017.02.005_bb0390","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/01.fjc.0000180902.78230.fd","article-title":"A review of the structural and functional features of olmesartan medoxomil, an angiotensin receptor blocker","volume":"46","author":"Mire","year":"2005","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/bs.podrm.2017.02.005_bb0395","unstructured":"http:\/\/newdrugapprovals.org\/tag\/olmesartan\/."},{"issue":"4","key":"10.1016\/bs.podrm.2017.02.005_bb0400","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0149-2918(03)80066-8","article-title":"Olmesartan medoxomil: an angiotensin II-receptor blocker","volume":"25","author":"Brousil","year":"2003","journal-title":"Clin. Ther."}],"container-title":["Profiles of Drug Substances, Excipients and Related Methodology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871512517300055?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871512517300055?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T09:34:26Z","timestamp":1761730466000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871512517300055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"ISBN":["9780128122266"],"references-count":80,"URL":"https:\/\/doi.org\/10.1016\/bs.podrm.2017.02.005","relation":{},"ISSN":["1871-5125"],"issn-type":[{"value":"1871-5125","type":"print"}],"subject":[],"published":{"date-parts":[[2017]]}}}